Info

Altus Pharmaceuticals Inc. (Altus) is a biopharmaceutical company focused on the development of oral and injectable protein therapeutics for gastrointestinal and metabolic disorders, with three product candidates in clinical development. The Company uses its protein crystallization technology to develop protein therapies. Its product candidates are designed to either substitute a protein that is in short supply in the body, or degrade toxic metabolites in the gut and remove them from the blood stream. It has initiated its Phase III clinical program for Trizytek (formerly ALTU-135) for the treatment of malabsorption due to exocrine pancreatic insufficiency and has completed a Phase II clinical trial of ALTU-238 in adults for the treatment of growth hormone deficiency. The Company is also conducting a Phase I clinical trial for ALTU-237. ALTU-237 is designed to treat hyperoxalurias. In addition, it has a pipeline of other product candidates in preclinical research and development.(Source: 10-K)